Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
Status:
Terminated
Trial end date:
2021-06-24
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenvatinib works when given together with standard of
care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated
thyroid cancer. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.